

Publikationen

Wissenschaftliche Originalarbeiten

1. Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE; **AIO Hepatobiliary Study Group**.
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
BMC Cancer. 2010 Aug 24;10:457
2. **Mohr, L.**, Banerjee, K., Kleinschmidt, M., Bartolome Rodriguez M., Wands, J.R.
Transgenic overexpression of insulin receptor substrate 1 in hepatocytes enhances hepatocellular proliferation in young mice only.
Hepatol Res. 2008 Dec;38(12):1233-40
3. Bartolome R.M., Ryu S.-M., Qian C., Geissler M., Prieto J., Blum H. E., **Mohr, L.**
Immunotherapy of murine hepatocellular carcinoma by α -fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression.
Hum Gene Ther. 2008 Jul;19(7):753-9
4. Willhauck M.J., Sharif Samani B.R., Klutz K., Cengic N., Wolf I., **Mohr L.**, Geissler M., Senekowitsch-Schidtko R., Göke B., Morris J.C., Spitzweg C.
Alpha-fetoprotein promotor-targeted sodium iodine symporter gene therapy of hepatocellular carcinoma
Gene Ther. 15:214-23, 2008
5. Kreutz C., Bartolome Rodriguez M., Maiwald T., Blum H.E., **Mohr, L.**, Timmer J.
An error model for protein quantification.
Bioinformatics 15:2747-53, 2007
6. Ali MY, Grimm CF, Ritter M, **Mohr L**, Allgaier HP, Weth R, Bocher WO, Endrulat K, Blum HE, Geissler M. Activation of dendritic cells by local ablation of hepatocellular carcinoma.
J Hepatol. 43(5):817-22, 2005.
7. Harder J., Mikesch K., **Mohr L.**, Blum H.E.
Seizures following Billroth II gastrectomy
Dtsch Med Wochenschr. 18: 574-6; 2005
8. Ritter M, Ali MY, Grimm CF, Weth R, **Mohr L**, Böcher WO, Endrulat K, Wedemeyer H, Blum HE, Geissler M. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
J Hepatol, 41: 999-1007, 2004
9. **Mohr, L.**, Yoon, S. K., Eastman, S. J., Chu, Q., Scheule, R. K., Scaglioni, P. P., Geissler, M., Heintges, T., Blum, H. E., and Wands, J. R.

- Cationic liposome-mediated gene delivery to the liver and to hepatocellular carcinomas in mice,
Hum Gene Ther. 12: 799-809., 2001.
10. **Mohr, L.**, Shankara, S., Yoon, S. K., Krohne, T. U., Geissler, M., Roberts, B., Blum, H. E., and Wands, J. R. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene,
Hepatology. 31: 606-14, 2000.
 11. **Mohr, L.**, Rainov, N. G., Mohr, U. G., and Wands, J. R. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma,
Cancer Gene Ther. 7: 1008-14, 2000.
 12. **Mohr, L.**, Schauer, J. I., Boutin, R. H., Moradpour, D., and Wands, J. R. Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery system,
Hepatology. 29: 82-9, 1999.
 13. **Mohr, L.**, Tanaka, S., and Wands, J. R. Ethanol inhibits hepatocyte proliferation in insulin receptor substrate 1 transgenic mice,
Gastroenterology. 115: 1558-65, 1998
 14. Krohne, T.U., Shankara, S., Geissler, M., Roberts, B.L., Wands, J.R., Blum, H.E., and **Mohr, L.** Mechanisms of cell death induced by the suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro,
Hepatology 34: 511-518, 2001.
 15. Yoon, S.-K., Armentano, D., Wands, J. R., and **Mohr, L.** Adenovirus- mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice.,
Cancer Gene Ther 8: 573-579, 2001.
 16. Geissler, M., **Mohr, L.**, Köhler, G., Grimm, C. F., Krohne, T. U., von Weizsäcker, F., Blum, H. E. Immunotherapy directed against α -fetoprotein results in autoimmune liver disease during liver regeneration,
Gastroenterology 121: 931-939, 2001
 17. Kroger, A., Ortmann, D., Krohne, T. U., **Mohr, L.**, Blum, H. E., Hauser, H., and Geissler, M. Growth suppression of the hepatocellular carcinoma cell line Hepa1-6 by an activatable interferon regulatory factor-1 in mice,
Cancer Res. 61: 2609-17., 2001.
 18. Yoon, S. K., **Mohr, L.**, O'Riordan, C. R., Lachapelle, A., Armentano, D., and Wands, J. R. Targeting a recombinant adenovirus vector to HCC cells using a bifunctional Fab-antibody conjugate,
Biochem Biophys Res Commun 272: 497-504, 2000.

19. Grimm, C. F., Ortmann, D., **Mohr, L.**, Michalak, S., Krohne, T. U., Meckel, S., Eisele, S., Encke, J., Blum, H. E., and Geissler, M.
Mouse alpha-fetoprotein-specific DNA-based immunotherapy of hepatocellular carcinoma leads to tumor regression in mice,
Gastroenterology 119: 1104-12, 2000.
20. Heintges, T., **Mohr, L.**, Hensel, F., Petry, W., Borchard, F., Haussinger, D., and Niederau, C.
Value of liver biopsy prior to interferon therapy for chronic viral hepatitis,
Dig Dis Sci 43: 1562-5, 1998.
21. Banerjee, K., **Mohr, L.**, Wands, J. R., and de la Monte, S. M.
Ethanol inhibition of insulin signaling in hepatocellular carcinoma cells,
Alcohol Clin Exp Res 22: 2093-101, 1998.
22. Heintges, T., **Mohr, L.**, Niederau, C., Scheiffele, F., Hensel, F., and Häussinger, D.
Quantitative hepatitis C RNA-polymerase chain reaction and detection with DNA-ELISA, **Hepatogastroenterology** 45: 1684-9, 1998.
23. Compagnon, B., Moradpour, D., Alford, D., Larsen, C., Stevenson, M., **Mohr, L.**, Wands, J., and Nicolau, C.
Enhanced gene delivery and expression in human hepatocellular carcinoma cells by cationic immunoliposomes,
J Liposome Res 7: 127-141, 1997
24. Tanaka, S., **Mohr, L.**, Schmidt, E. V., Sugimachi, K., and Wands, J. R.
Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes,
Hepatology 26: 598-604, 1997.
25. Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C.M., **Mohr, L.**, and Häussinger, D.
Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B,
N Engl J Med 334: 1422-7, 1996.
26. Peters, T., **Mohr, L.**, Scheiffele, F., Schlayer, H. J., Preisler, S., Berthold, H., Gerok, W., and Rasenack, J.
Antibodies and viremia in acute post-transfusion hepatitis C: a prospective study
J Med Virol 42: 420-7, 1994

Übersichtsarbeiten

1. Allgaier HP, Arnold C, Baumert TF, Becker G, Geißler M, Hafkemeyer P, Harder J, Heim MH, Huber R, Kern WV, **Mohr L**, Moradpour D, Offensperger S, Offensperger WB, Spangenberg HC, Thimme R, Walter E, von Weizsäcker F.
Dtsch Med Wochenschr. 143:40-45, 2018
2. Spangenberg HC, Thimme R, **Mohr L**, Blum HE.
The hepatocellular carcinoma: alternative therapeutical strategies.
Zentralbl Chir. 132:322-7, 2007
3. Spangenberg H.C., **Mohr L.**, Blum H.E.
Regional therapy of liver tumors
Internist 48: 40-45 2007
4. **Mohr L.**
Innovative Therapieansätze des Hepatozellulären Karzinoms.
Schweiz Rundsch Med Prax, 96: 553-62; 2007
5. **Mohr L.**, Spangenberg H.-C., Harder J., Blum H. E.
Lokoregionäre Therapie von Lebermetastasen.
Klinikerzt, 34; 273-278, 2005.
6. **Mohr L.**, Yeung A, Aloman C, Wittrup D, Wands JR.
Antibody-directed therapy for human hepatocellular carcinoma.
Gastroenterology 127, 225-231, 2004
7. Zuber-Jerger I, Geissler M, Spangenberg HC, **Mohr L**, Weizsäcker F, Blum H E.
Local ablation of malignant lesions of the liver – potential applikations and limitations of the different methods.
Z Gastroenterol. 42; 31-38, 2004
8. Spangenberg HC, Zuber-Jerger I, **Mohr L**, Thimme R and Blum H E.
Diagnosis and treatment of hepatocellular carcinoma.
Dtsch Med Wochenschr. 20; 368-372, 2004
9. **Mohr L.**, Geissler M., Blum H. E .
Gen-und Immuntherapie des hepatozellulären Karzinoms: Fakten und Fiktionen im Jahr 2003.
Chir. Gastroenterol. 19:253-260, 2003
10. Geissler, M., **Mohr, L.**, Ali MY, Grimm CF, Ritter M und Blum, H E.
Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Z Gastroenterol. 41; 1101-1110, 2003
11. **Mohr, L.**, Geissler, M.
Gentherapie: Neue Entwicklungen,
Schweiz Rundsch Med Prax 18;2227-2235, 2002

12. **Mohr, L.**, Geissler, M., and Blum H E.
Gene therapy for malignant liver disease,
Exp Opin Biol Ther 2:163-175, 2002
13. Geissler M., **Mohr L.**, Blum H.E.
Cyclooxygenase, Polypen und kolorektales Karzinom.
Dtsch Med Wochenschr 127: 1256-1258, 2002.
14. Geissler, M., **Mohr, L.**, und Blum, H E.
Immuntherapie des hepatozellulären Karzinoms
Dtsch Med Wochenschr 126:1464-1466, 2001
15. **Mohr, L.**, Heintges, T., Hensel, F., Niederau, C., and Haussinger, D.
Treatment of autoimmune cholangitis,
Dig Dis Sci 43: 2160-3, 1998.
16. Wands, J. R., Lavaissiere, L., Moradpour, D., de la Monte, S., **Mohr, L.**, Nicolau, C., Tanaka, S. Immunological approach to hepatocellular carcinoma,
J Viral Hepat 4: 60-74, 1997.
17. Wands, J. R., Geissler, M., Putlitz, J. Z., Blum, H., Wezsacker, F. V., **Mohr, L.**, Yoon, S. K., Melegari, M., and Scaglioni, P. P. Nucleic acid-based antiviral and gene therapy of chronic hepatitis B infection,
J Gastroenterol Hepatol 12: S354-69, 1997.
18. Heintges, T., Niederau, C., **Mohr, L.**, Hensel, F., and Haussinger, D. Diagnose und Therapie der chronischen Virushepatitis,
Z Gastroenterol 34: 446-56, 1996.
19. Heintges, T., **Mohr, L.**, and Niederau, C. Therapie der chronischen Virushepatitis,
Muench Med Wschr 137: 275-279, 1995.
20. Heintges, T., **Mohr, L.**, Niederau, C., and Strohmeyer, G.
Diagnose und Therapie der autoimmunen Hepatitis,
Z Gastroenterol 33: 462-7, 1995.
21. Niederau, C., Ehlen, C., Littauer, A., Heintges, T., **Mohr, L.**
Die Behandlung des Morbus Gaucher mit einer modifizierten Glukocerebrosidase,
Int. Praxis. 34: 878-882, 1994.
22. Heintges, T., **Mohr, L.**, and Niederau, C.
Epidemiologie und Klinik der chronischen Virushepatitis
Dtsch Med Wochenschr 119: 1365-70, 1994